This site is intended for health professionals only
Sunday 16 June 2019
Share |

Topic: Central Nervous System

February 25, 2015
A new nationwide online and telephone service helping people take part in dementia research studies has been launched - the first of its kind in the UK. The ‘matchmaking’ scheme is a collaboration between the National Institute for Health Research (NIHR), Alzheimer’s Research UK, Alzheimer’s Society and Alzheimer Scotland and is funded by the Department of Health and will be implemented locally through the NIHR Clinical Research Network: Yorkshire and Humber.

A new nationwide online and telephone service helping people take part in dementia research studies has been launched - the first of its kind in the UK. The ‘matchmaking’ scheme is a collaboration between the National Institute for Health Research (NIHR), Alzheimer’s Research UK, Alzheimer’s Society and Alzheimer Scotland and is funded by the Department of Health and will be implemented locally through the NIHR Clinical Research Network: Yorkshire and Humber.

 

December 9, 2014
A novel Parkinson's vaccine will now be tested in a clinical Phase I trial in Austria by an EU-funded consortium. The Austrian biotech company AFFiRiS AG developed the vaccine, which targets a protein called alpha-Synuclein. The protein plays a key role in the onset and progression of Parkinson's as well as multiple system atrophy (MSA), an orphan disease. This vaccine has the potential to modify disease progression, rather than only symptomatic improvements available with current treatment strategies. The start of the Parkinson's trial follows in the wake of positive results from a similar Parkinson's vaccine trial recently conducted by AFFiRiS with support from the Michael J. Fox Foundation.
October 10, 2014
Bayer HealthCare announces it is pleased that the National Institute for Health and Care Excellence (NICE) clinical guideline for the management of Multiple Sclerosis (MS) in primary and secondary care (CG186) recognises the multi-faceted nature of the disease and the complex needs of people with MS. Bayer welcomes the recommendation that MS patients should have a single point of contact and a comprehensive annual review but are disappointed that the guideline did not recommend Sativex® as a treatment option for moderate to severe spasticity.

Bayer HealthCare announces it is pleased that the National Institute for Health and Care Excellence (NICE) clinical guideline for the management of Multiple Sclerosis (MS) in primary and secondary care (CG186) recognises the multi-faceted nature of the disease and the complex needs of people with MS. Bayer welcomes the recommendation that MS patients should have a single point of contact and a comprehensive annual review but are disappointed that the guideline did not recommend Sativex® as a treatment option for moderate to severe spasticity. (1)
 

October 17, 2012
Rufinamide is an anti-epileptic drug that received marketing authorisation as adjunctive therapy in Lennox-Gastaut syndrome (LGS) from the European commission in January 2007 and the FDA in November 2008. It has a different mode of action from other anti-epileptic drugs: it modulates the frequency of sodium-dependent neuronal action potentials, although the precise mechanism is yet to be determined. The Cmax is approximately six hours and the half-life is six-to-ten hours in healthy volunteers. Sodium valproate may decrease the clearance. It is not strongly protein bound. Although licensed only for the treatment of LGS, efficacy has also been demonstrated in other epilepsy syndromes and seizure types, notably partial seizures.

teaser

August 22, 2012
While researchers have speculated that changes in brain blood flow due to vein abnormalities contribute to multiple sclerosis (MS) disease severity, a study published online Aug. 21 in Radiology has demonstrated this may not be the case as these abnormalities were shown not to be specific to MS.

teaser

July 18, 2011
Study shows benefits of trastuzumab and chemotherapy in HER2-positive metastatic breast cancer patients

teaser

July 6, 2011
New technology-based test for cystic fibrosis is in Astra Biotech GmbH

teaser

June 30, 2011
Global pharmaceutical company submits application to EMA.

teaser

June 10, 2011
New post hoc analyses examined the effects on daytime functioning, daytime symptoms, pain RLS

teaser

June 9, 2011
Post hoc analysis from RECOVER study examined effects on surrogate markers of mood and anhedonia

teaser

June 2, 2011
Swedish study shows many patients receive wrong dementia diagnosis

teaser

June 1, 2011
Update on Lundbeck's total number of voting rights and total share capital

teaser

May 26, 2011
Launch of Sativex

teaser

May 23, 2011
New initiative during MS Week could give first true picture of MS in the UK

teaser

February 19, 2009
In-line with UCB's SHAPE programme to focus on its core competencies Walloon Region supports local economical development Biologics pilot plant expected to become operational early 2012

teaser

February 9, 2009
Lundbeck to acquire US-based Ovation Pharmaceuticals Inc, a specialty pharmaceutical company focusing on CNS disorders

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine